Quest Diagnostics EBITDA Margin 2010-2025 | DGX

Quest Diagnostics ebitda margin for the quarter ending March 31, 2025 was 18.79%.

  • Quest Diagnostics average ebitda margin for 2024 was 18.35%, a 5.28% increase from 2023.
  • Quest Diagnostics average ebitda margin for 2023 was 17.43%, a 21.91% increase from 2022.
  • Quest Diagnostics average ebitda margin for 2022 was 22.32%, a 17.91% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Quest Diagnostics EBITDA Margin 2010-2025 | DGX

  • Quest Diagnostics average ebitda margin for 2024 was 18.35%, a 5.28% increase from 2023.
  • Quest Diagnostics average ebitda margin for 2023 was 17.43%, a 21.91% increase from 2022.
  • Quest Diagnostics average ebitda margin for 2022 was 22.32%, a 17.91% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
DaVita (DVA)$11.2B
Encompass Health (EHC)$10.4B
Chemed (CHE)$8.5B
Option Care Health (OPCH)$5.3B
Elanco Animal Health (ELAN)$4.2B
RadNet (RDNT)$3.7B
Amedisys (AMED)$3B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$1.8B
Astrana Health (ASTH)$1.6B
U.S Physical Therapy (USPH)$1B
Pennant (PNTG)$907M
Aveanna Healthcare Holdings (AVAH)$886M
Atai Life Sciences (ATAI)$294M
Daxor (DXR)$36M
Ontrak (OTRK)$6M
MEDIROM Healthcare Technologies (MRM)$4M
Psychemedics (PMD)$0M